CRONCronos Group Inc.
The schedule
- Thu15Oct
Anticipated regulatory updates regarding the federal scheduling of cannabis. The market will react to guidance from President Trump's administration regarding safe banking and interstate commerce frameworks.
- Wed20Jan
With nearly $1B in total equity and minimal debt, activist or institutional pressure is expected to compel management to clarify its M&A strategy or outline capital return frameworks.
- Sun7Feb
Q3 2026 earnings will offer visibility into international medical cannabis sales, particularly in Germany and Israel, acting as a counterbalance to domestic North American regulatory headwinds.
- Sun9May
Full-year 2026 results will definitively show whether CRON achieved its operating profitability pivot, confirming whether the strong cash flow metrics seen in early 2026 were structural or cyclical.
- Sun8Aug
The first quarter of 2027 will test CRON's capacity to maintain its premium valuation against industry peers, relying on consistent operational execution.
Past
- Sun9Aug
Cronos will report Q2 2026 earnings, providing an update on its path to sustained free cash flow generation and the market share of its Spinach brand in Canada. The market will look to see if the recent 38% YoY revenue growth trajectory remains intact.
- Sun10May
Actual outcome: Mixed · $2.79 at outcome
Price at outcome date was between bear floor ($2.20) and bull target ($2.90).
Price at outcome date was between bear floor ($2.20) and bull target ($2.90).